191 related articles for article (PubMed ID: 14702193)
1. Attachment of the soluble complement regulator factor H to cell and tissue surfaces: relevance for pathology.
Józsi M; Manuelian T; Heinen S; Oppermann M; Zipfel PF
Histol Histopathol; 2004 Jan; 19(1):251-8. PubMed ID: 14702193
[TBL] [Abstract][Full Text] [Related]
2. Mutations in factor H reduce binding affinity to C3b and heparin and surface attachment to endothelial cells in hemolytic uremic syndrome.
Manuelian T; Hellwage J; Meri S; Caprioli J; Noris M; Heinen S; Jozsi M; Neumann HP; Remuzzi G; Zipfel PF
J Clin Invest; 2003 Apr; 111(8):1181-90. PubMed ID: 12697737
[TBL] [Abstract][Full Text] [Related]
3. Mutations of factor H impair regulation of surface-bound C3b by three mechanisms in atypical hemolytic uremic syndrome.
Lehtinen MJ; Rops AL; Isenman DE; van der Vlag J; Jokiranta TS
J Biol Chem; 2009 Jun; 284(23):15650-8. PubMed ID: 19351878
[TBL] [Abstract][Full Text] [Related]
4. Self-nonself discrimination by the complement system.
Meri S
FEBS Lett; 2016 Aug; 590(15):2418-34. PubMed ID: 27393384
[TBL] [Abstract][Full Text] [Related]
5. Deregulation of Factor H by Factor H-Related Protein 1 Depends on Sialylation of Host Surfaces.
Dopler A; Stibitzky S; Hevey R; Mannes M; Guariento M; Höchsmann B; Schrezenmeier H; Ricklin D; Schmidt CQ
Front Immunol; 2021; 12():615748. PubMed ID: 33732239
[TBL] [Abstract][Full Text] [Related]
6. Staphylococcal Ecb protein and host complement regulator factor H enhance functions of each other in bacterial immune evasion.
Amdahl H; Jongerius I; Meri T; Pasanen T; Hyvärinen S; Haapasalo K; van Strijp JA; Rooijakkers SH; Jokiranta TS
J Immunol; 2013 Aug; 191(4):1775-84. PubMed ID: 23863906
[TBL] [Abstract][Full Text] [Related]
7. Complement and diseases: defective alternative pathway control results in kidney and eye diseases.
Zipfel PF; Heinen S; Józsi M; Skerka C
Mol Immunol; 2006 Jan; 43(1-2):97-106. PubMed ID: 16026839
[TBL] [Abstract][Full Text] [Related]
8. Disturbed sialic acid recognition on endothelial cells and platelets in complement attack causes atypical hemolytic uremic syndrome.
Hyvärinen S; Meri S; Jokiranta TS
Blood; 2016 Jun; 127(22):2701-10. PubMed ID: 27006390
[TBL] [Abstract][Full Text] [Related]
9. Mutations in Complement Factor H Impair Alternative Pathway Regulation on Mouse Glomerular Endothelial Cells in Vitro.
Loeven MA; Rops AL; Lehtinen MJ; van Kuppevelt TH; Daha MR; Smith RJ; Bakker M; Berden JH; Rabelink TJ; Jokiranta TS; van der Vlag J
J Biol Chem; 2016 Mar; 291(10):4974-81. PubMed ID: 26728463
[TBL] [Abstract][Full Text] [Related]
10. Binding of the human complement regulators CFHR1 and factor H by streptococcal collagen-like protein 1 (Scl1) via their conserved C termini allows control of the complement cascade at multiple levels.
Reuter M; Caswell CC; Lukomski S; Zipfel PF
J Biol Chem; 2010 Dec; 285(49):38473-85. PubMed ID: 20855886
[TBL] [Abstract][Full Text] [Related]
11. Complement activation in diseases presenting with thrombotic microangiopathy.
Meri S
Eur J Intern Med; 2013 Sep; 24(6):496-502. PubMed ID: 23743117
[TBL] [Abstract][Full Text] [Related]
12. Disease-associated N-terminal complement factor H mutations perturb cofactor and decay-accelerating activities.
Pechtl IC; Kavanagh D; McIntosh N; Harris CL; Barlow PN
J Biol Chem; 2011 Apr; 286(13):11082-90. PubMed ID: 21270465
[TBL] [Abstract][Full Text] [Related]
13. Binding of complement factor H to endothelial cells is mediated by the carboxy-terminal glycosaminoglycan binding site.
Jokiranta TS; Cheng ZZ; Seeberger H; Jòzsi M; Heinen S; Noris M; Remuzzi G; Ormsby R; Gordon DL; Meri S; Hellwage J; Zipfel PF
Am J Pathol; 2005 Oct; 167(4):1173-81. PubMed ID: 16192651
[TBL] [Abstract][Full Text] [Related]
14. Recognition of malondialdehyde-modified proteins by the C terminus of complement factor H is mediated via the polyanion binding site and impaired by mutations found in atypical hemolytic uremic syndrome.
Hyvärinen S; Uchida K; Varjosalo M; Jokela R; Jokiranta TS
J Biol Chem; 2014 Feb; 289(7):4295-306. PubMed ID: 24344133
[TBL] [Abstract][Full Text] [Related]
15. Unraveling the Effect of a Potentiating Anti-Factor H Antibody on Atypical Hemolytic Uremic Syndrome-Associated Factor H Variants.
Dekkers G; Brouwer MC; Jeremiasse J; Kamp A; Biggs RM; van Mierlo G; Lauder S; Katti S; Kuijpers TW; Rispens T; Jongerius I
J Immunol; 2020 Oct; 205(7):1778-1786. PubMed ID: 32848031
[TBL] [Abstract][Full Text] [Related]
16. Hijacking Factor H for Complement Immune Evasion.
Moore SR; Menon SS; Cortes C; Ferreira VP
Front Immunol; 2021; 12():602277. PubMed ID: 33717083
[TBL] [Abstract][Full Text] [Related]
17. The binding of factor H to a complex of physiological polyanions and C3b on cells is impaired in atypical hemolytic uremic syndrome.
Ferreira VP; Herbert AP; Cortés C; McKee KA; Blaum BS; Esswein ST; Uhrín D; Barlow PN; Pangburn MK; Kavanagh D
J Immunol; 2009 Jun; 182(11):7009-18. PubMed ID: 19454698
[TBL] [Abstract][Full Text] [Related]
18. Monomeric CRP contributes to complement control in fluid phase and on cellular surfaces and increases phagocytosis by recruiting factor H.
Mihlan M; Stippa S; Józsi M; Zipfel PF
Cell Death Differ; 2009 Dec; 16(12):1630-40. PubMed ID: 19680263
[TBL] [Abstract][Full Text] [Related]
19. Hemolytic uremic syndrome: a factor H mutation (E1172Stop) causes defective complement control at the surface of endothelial cells.
Heinen S; Józsi M; Hartmann A; Noris M; Remuzzi G; Skerka C; Zipfel PF
J Am Soc Nephrol; 2007 Feb; 18(2):506-14. PubMed ID: 17229916
[TBL] [Abstract][Full Text] [Related]
20. Complement-regulatory biomaterial coatings: Activity and selectivity profile of the factor H-binding peptide 5C6.
Bechtler C; Koutsogiannaki S; Umnyakova E; Hamid A; Gautam A; Sarigiannis Y; Pouw RB; Lamers C; Rabbani S; Schmidt CQ; Lambris JD; Ricklin D
Acta Biomater; 2023 Jan; 155():123-138. PubMed ID: 36328123
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
